Radiation dose key to lasting brachytherapy effect in treating prostate cancer
Permanent brachytherapy's long-term success depends on delivery of a high biological effective dose of radiation.
Key Points
Chicago-Permanent brachytherapy's long-term success in prostate cancer depends on delivery of a high biological effective dose (BED) of radiation, data from more than 2,000 cases showed.
Freedom from biochemical failure, local control, and cause-specific survival improved as BED increased, and BED had a significant association with all three outcomes. Patients in all risk categories benefited from a high BED, according to the report, which was presented at the AUA annual meeting.
"Long-term oncologic outcomes with permanent prostate brachytherapy were excellent, but a high biologic effective dose has to be delivered for successful biochemical freedom from failure, local control, and cause-specific survival," said Nelson N. Stone, MD, clinical professor of urology at Mount Sinai School of Medicine in New York.
Patients were grouped by BED: ≤150 Gy, >150 to 200 Gy, and >200 Gy. Dr. Stone reported that 526 patients (26.6%) had 2-year multi-core prostate biopsy, which was repeated yearly if it read positive or in the case of a rising PSA level.
Median PSA was 7.1 ng/mL and ranged from 0.6 to 300 ng/mL. About two-thirds of the patients (68.9%) had clinical stage ≤T2a, and a similar proportion (67.6%) had Gleason score <7. Risk characteristics were low in 964 patients (45.7%), intermediate in 499 (23.6%), and high in 648 (30.7%). The median follow-up was 6 years and ranged from 2 to 17 years. The median BED was 198 Gy, with a range of 15.1 to 292 Gy.
At 12 years, biochemical freedom from failure was 78.6%, freedom from metastases was 95.2%, and cause-specific survival was 94.5%. Analysis by BED revealed a biochemical freedom from failure of 87.3% in patients who received a BED >200 Gy, 83.6% when the BED was >150 to 200 Gy, and 59% when the BED was 150 Gy or less. Analysis by patient risk showed BED was a significant predictor of biochemical freedom from failure regardless of baseline risk (p=.012 to p<.001).
The proportion of patients with positive biopsy results decreased from 21.5% among patients who received the lowest BEDs, to 5.6% for the intermediate BEDs, to 2.1% for BED >200 Gy (p<.001). The 12-year biochemical freedom from failure rate was 78% in patients with negative biopsies versus 42% for those with positive biopsies (p<.001).
In a regression analysis of predictors of cause-specific survival, only Gleason score (p=.000) and BED (p=.027) emerged as statistically significant factors.
Dr. Stone is an owner of Prologics, LLC.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
